ConductScience.org, home

Paper41550465

Low Dose of IL-2 Application for Graft-Versus-Host Disease Prophylaxis Following Haploidentical Stem Cell Transplantation.

Xu ZL and 13 others. MedComm (2020), 2026. Cited by 0 papers, by iCite.

Cite this record

ConductScience Library. Low Dose of IL-2 Application for Graft-Versus-Host Disease Prophylaxis Following Haploidentical Stem Cell Transplantation. Papers, record 41550465. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41550465

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Low Dose of IL-2 Application for Graft-Versus-Host Disease Prophylaxis Following Haploidentical Stem Cell Transplantation.
PubMed
Journal
MedComm (2020)
PubMed
Year
2026
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
0
iCite
Revised in PubMed
2026-09-26
PubMed

Authors14

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Xu ZLZheng-Li
2Lv MMeng
3Yu XXXing-Xing
4Ding YYYi-Yang
5Han TTTing-Ting
6Fu HXHai-Xia
7Zhang YYYuan-Yuan
8Mo XDXiao-Dong
9Sun YQYu-Qian
10Xu LPLan-Ping
11Zhang XHXiao-Hui
12Wang YYu
13Huang XJXiao-Junhttps://orcid.org/0000-0002-2145-6643
14Zhao XYXiang-Yu

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References37

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
122749354NK cell-derived interferon-γ orchestrates cellular dynamics and the differentiation of monocytes into dendritic cells at the site of infection.Immunity2012https://conductscience.org/library/papers/22749354PubMed
227073224Efficacy, durability, and response predictors of low-dose interleukin-2 therapy for chronic graft-versus-host disease.Blood2016https://conductscience.org/library/papers/27073224PubMed
324319201Natural killer cells and regulatory T cells: how to manipulate a graft for optimal GVL.Hematology Am Soc Hematol Educ Program2013https://conductscience.org/library/papers/24319201PubMed
424686272Ultra-low dose interleukin-2 promotes immune-modulating function of regulatory T cells and natural killer cells in healthy volunteers.Mol Ther2014https://conductscience.org/library/papers/24686272PubMed
524719405Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein.Blood2014https://conductscience.org/library/papers/24719405PubMed
618804038Combination therapy using IL-2 and anti-CD25 results in augmented natural killer cell-mediated antitumor responses.Biol Blood Marrow Transplant2008https://conductscience.org/library/papers/18804038PubMed
712480696CD56bright natural killer cells are present in human lymph nodes and are activated by T cell-derived IL-2: a potential new link between adaptive and innate immunity.Blood2003https://conductscience.org/library/papers/12480696PubMed
820389017Altered regulatory T cell homeostasis in patients with CD4+ lymphopenia following allogeneic hematopoietic stem cell transplantation.J Clin Invest2010https://conductscience.org/library/papers/20389017PubMed
924573552Ultra low-dose IL-2 for GVHD prophylaxis after allogeneic hematopoietic stem cell transplantation mediates expansion of regulatory T cells without diminishing antiviral and antileukemic activity.Clin Cancer Res2014https://conductscience.org/library/papers/24573552PubMed
1039562716Immunological reconstitution and infections after alloHCT - a comparison between post-transplantation cyclophosphamide, ATLG and non-ATLG based GvHD prophylaxis.Bone Marrow Transplant2025https://conductscience.org/library/papers/39562716PubMed
1137968447Peripheral blood stem cell transplantation from haploidentical related donor could achieve satisfactory clinical outcomes for intermediate- or high-risk adult acute myeloid leukemia patients.Bone Marrow Transplant2024https://conductscience.org/library/papers/37968447PubMed
1212925844CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation.Nat Med2003https://conductscience.org/library/papers/12925844PubMed
1337662885Mini-dose methotrexate combined with methylprednisolone as a first-line treatment for acute graft-versus-host disease: A phase 2 trial.J Transl Int Med2023https://conductscience.org/library/papers/37662885PubMed
1438937803Memory T-cell enriched haploidentical transplantation with NK cell addback results in promising long-term outcomes: a phase II trial.J Hematol Oncol2024https://conductscience.org/library/papers/38937803PubMed
1538664766Mini-dose methotrexate combined with methylprednisolone for the initial treatment of acute GVHD: a multicentre, randomized trial.BMC Med2024https://conductscience.org/library/papers/38664766PubMed
1625085354Favorable impact of natural killer cell reconstitution on chronic graft-versus-host disease and cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation.Haematologica2014https://conductscience.org/library/papers/25085354PubMed
1728104702IL-2 promotes early Treg reconstitution after allogeneic hematopoietic cell transplantation.Haematologica2017https://conductscience.org/library/papers/28104702PubMed
1837827864IL-2-driven CD8+ T cell phenotypes: implications for immunotherapy.Trends Immunol2023https://conductscience.org/library/papers/37827864PubMed
1937363859Antibody-mediated pathogenesis of chronic GVHD through DBY/HLA class II complexes and induction of a GVL effect.Blood2023https://conductscience.org/library/papers/37363859PubMed
2011896281Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants.Science2002https://conductscience.org/library/papers/11896281PubMed

See all 37 referencesDownload CSV of references

Cited by1

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 0 citations.

PMIDTitleJournalYearIn Papers
41550465Low Dose of IL-2 Application for Graft-Versus-Host Disease Prophylaxis Following Haploidentical Stem Cell Transplantation.MedComm (2020)2026https://conductscience.org/library/papers/41550465

Source PubMed

Download CSV of cited by

Genes9

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/41550465

GET https://conductscience.org/api/papers/v1/41550465/references?page=2